Evidence map›Paper›PMID 29386396›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2018

Respecifying human iPSC-derived blood cells into highly engraftable hematopoietic stem and progenitor cells with a single factor.

Yu-Ting Tan, Lin Ye, Fei Xie, Ashley I Beyer, Marcus O Muench, Jiaming Wang, Zhu Chen, Han Liu, Sai-Juan Chen, Yuet Wai Kan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed
3.5field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 65 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Cell and Gene Therapy for Anemia: Hematopoietic Stem Cells and Gene Editing.International journal of molecular sciences · 2021
    Review
  19. Review
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Yu-Ting TanState Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, Rui-Jin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
Lin YeDepartment of Medicine, University of California, San Francisco, CA 94143.
Fei XieDepartment of Medicine, University of California, San Francisco, CA 94143.
Ashley I BeyerBlood Systems Research Institute, San Francisco, CA 94118.
Marcus O MuenchBlood Systems Research Institute, San Francisco, CA 94118.
Jiaming WangDepartment of Medicine, University of California, San Francisco, CA 94143.
Zhu ChenState Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, Rui-Jin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
Han LiuState Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, Rui-Jin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China; liuhan68@sjtu.edu.cn sjchen@stn.sh.cn yw.kan@ucsf.edu.
Sai-Juan ChenState Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, Rui-Jin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China; liuhan68@sjtu.edu.cn sjchen@stn.sh.cn yw.kan@ucsf.edu.
Yuet Wai KanDepartment of Medicine, University of California, San Francisco, CA 94143; liuhan68@sjtu.edu.cn sjchen@stn.sh.cn yw.kan@ucsf.edu.
University of California, San Francisco · USShanghai Institute of Hematology · CNBlood Systems Research Institute · USShanghai Jiao Tong University · CN

Funding

Research BaseP30DK063720 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GERMAN, MICHAEL S · 2003 to 2019
$21.8M
Reprogramming iPS Cells with Exogenous and Endogenous Transcription Factor GenesP01DK088760 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GRUENERT, DIETER C · 2011 to 2015
$6.5M
NIDDK NIH HHS P01 DK088760NIDDK NIH HHS P30 DK063720
6 · The paper itself

Abstract

Derivation of human hematopoietic stem cells (HSCs) from induced pluripotent stem cells (iPSCs) offers considerable promise for cell therapy, disease modeling, and drug screening. However, efficient derivation of functional iPSC-derived HSCs with in vivo engraftability and multilineage potential remains challenging. Here, we demonstrate a tractable approach for respecifying iPSC-derived blood cells into highly engraftable hematopoietic stem and progenitor cells (HSPCs) through transient expression of a single transcription factor,

Indexed as

Erythroid CellsAnimalsCell DifferentiationGene Expression RegulationHematopoietic Stem CellsHumansInduced Pluripotent Stem CellsMiceMyeloid-Lymphoid Leukemia ProteinOncogene Proteins, FusionTeratomaMLL-AF4 fusion protein, humanMyeloid-Lymphoid Leukemia ProteinOncogene Proteins, Fusionengraftabilityhematopoietic stem cellshuman induced pluripotent stem cellsleukemiaMLL-AF4

Identifiers

PMID29386396
PMCPMC5834708
OpenAlexW2793637173

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.